JAKARTA – Obesity drugs such as Ozempic and Mounjaro can help lose weight. However, a new study found that most of these drugs have not been shown to significantly improve quality of life after one year of use
Quoted from Euronews, Saturday, July 11, the study published in the journal The BMJ analyzed 262 clinical trials involving about 100,000 participants and 19 types of drugs
The results showed that greater weight loss was consistently associated with increased adverse events and discontinuation of treatment
“Most active substances do not significantly improve quality of life and only a few show benefits for the heart and blood vessels,” the researchers wrote
In the clinical trial, participants filled out a standard questionnaire on health-related quality of life. Researchers then compared the change in scores between drug users and participants who only underwent lifestyle changes
In most major treatments, changes in quality of life scores have not been judged large enough to be considered medically important
Tirzepatide, the active substance in Mounjaro and Zepbound, as well as CagriSema produced the greatest weight loss in overweight adults. CagriSema has not yet received approval for clinical use
The injectable semaglutide used in Ozempic and Wegovy has the strongest evidence in reducing the risk of death and severe events in the heart and blood vessels
However, tirzepatide and semaglutide are also associated with a decrease in lean body mass, which can be detrimental to health. Lean body mass is the total body weight other than fat
Low lean body mass is associated with increased risk of falls, fractures, and premature death
The authors assessed that weight loss alone is not enough to measure the success of obesity treatment. Health conditions, ability to move, and quality of life also need to be taken into account
Euronews noted that most of the clinical trials analyzed had a short monitoring period. Longer studies are still needed to understand the long-term impact of new drugs
Findings on quality of life also need to be read carefully. Researchers not involved in the study said each patient’s experience is different and not always captured by standard questionnaires
“Quality of life is complex and different for everyone,” said Marie Spreckley of the University of Cambridge
According to Spreckley, standard measuring tools do provide important information. However, these tools may not capture the entire experience of treatment that is considered important by people with obesity
Obesity is now increasingly understood as a complex chronic disease. The study’s authors warn that using weight as the only measure can simplify the benefits and risks of treatment, while reinforcing the stigma against people with obesity
José M. Ordovás of Tufts University said the study’s findings were in line with existing knowledge
“A number of drugs do produce large weight loss, but losing weight does not automatically improve all aspects of health,” said Ordovás, who was not involved in the study
“The scales only tell part of the story, not the whole,” he said
According to Ordovás, the success of treating obesity should be judged from health, the ability of the body to carry out activities, and quality of life, not just from the number of kilograms that fall
The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language.
(system supported by DigitalSiber.id)
Add VOI as a Preferred Source
Follow VOI news updates across Google.
+
Most Popular Tags
#Prabowo Subianto#donald trump#2026 World Cup#venezuela#konflik timur tengah
Popular
| TECHNOLOGY
More than 100 Celebrities Enter iQIYI AI Talent, Several Celebrities Deny Giving Consent
11 Juli 2026, 20:45
| SPORTS
NOC Assures Indonesia’s Readiness to Face the 2026 Asian Games
11 Juli 2026, 22:05
| NEWS
Mojtaba Khamenei: Iran Promises Revenge for Ali Khamenei’s Death
11 Juli 2026, 21:15
| MOBIL
Wuling Aira EV Ready to Launch at GIIAS 2026, Price Below IDR 200 Million?
11 Juli 2026, 21:45
| ECONOMY
US Energy Giant’s Profitable Boosting Oil Prices, Expensive Gasoline a Problem for Trump
12 Juli 2026, 02:15
